Abemaciclib [1], hormonal contraceptives ---> SmPC of [1] of EMA
It is currently unknown whether abemaciclib may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives are advised to add a barrier method.
Acenocoumarol [1], oral contraceptives ---> SmPC of [1] of eMC
The co-administration may decrease the anticoagulant effect
Acitretin [1], oral contraceptives ---> SmPC of [1] of eMC
Low dose progesterone-only products (minipills) may be an inadequate method of contraception during acitretin therapy
Ajmaline, oral contraceptives
The co-administration of ajmaline with hormones increases the frequency of long-lasting cholestasis
Albiglutide [1], oral contraceptives ---> SmPC of [1] of EMA
Albiglutide (50 mg weekly at steady-state) had no clinically relevant effects on the steady-state pharmacokinetics of a combination oral contraceptive containing norethindrone 0.5 mg and ethinyl estradiol 0.035 mg.
Alectinib [1], oral contraceptives ---> SmPC of [1] of EMA
The effectiveness of concomitant administration of oral contraceptives may be reduced.
Alipogene tiparvovec [1], oral contraceptives ---> SmPC of [1] of EMA
Oral contraceptive use is contraindicated in LPLD patients as this may exacerbate the underlying disease.
Alitretinoin [1], oral contraceptives ---> SmPC of [1] of eMC
Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. John's Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough bleeding on oral contraceptives
Allopurinol/lesinurad [1], hormonal contraceptives ---> SmPC of [1] of EMA
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness
Alpelisib [1], hormonal contraceptives ---> SmPC of [1] of EMA
No clinical studies were conducted assessing the drug-drug-interaction potential between alpelisib and hormonal contraceptives.
Alprazolam, oral contraceptives
Concomitant use of alprazolam and strong CYP3A4 inhibitors should be done with caution a significant dose reduction should be considered
Ambrisentan [1], oral contraceptives ---> SmPC of [1] of EMA
Ambrisentan would not be expected to significantly affect exposure to oestrogen- or progestogen- based contraceptives.
Aminophylline [1], oral contraceptives ---> SmPC of [1] of eMC
Oral contraceptives may decrease aminophylline clearance resulting in increased plasma theophylline concentrations and the potential for increased toxicity
Amoxicillin, oral contraceptives
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Ampicillin [1], oral contraceptives ---> SmPC of [1] of eMC
In common with other broad-spectrum antibiotics ampicillin may reduce the efficacy of oral contraceptives and patients should be warned accordingly.
Anagrelide [1], oral contraceptives ---> SmPC of [1] of EMA
Anagrelide may cause intestinal disturbance in some patients and compromise the absorption of hormonal oral contraceptives.
Antibiotics, contraceptives
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Antibiotics, oral contraceptives ---> SmPC of [tigecycline] of EMA
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Antidiabetics, oral contraceptives
Effect on glucose tolerance
Apremilast [1], oral contraceptives ---> SmPC of [1] of EMA
There was no pharmacokinetic drug-drug interaction between apremilast and oral contraceptives containing ethinyl estradiol and norgestimate. Apremilast can be co-administered with oral contraceptives.
Aprepitant [1], oral contraceptives ---> SmPC of [1] of EMA
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of aprepitant
Asparaginase [1], oral contraceptives ---> SmPC of [1] of EMA
Since an indirect interaction between components of the oral contraception and asparaginase cannot be ruled out, oral contraceptives are not considered sufficiently safe in such clinical situation
Atazanavir [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration of REYATAZ with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate or norethindrone has not been studied, and therefore should be avoided
Atazanavir/cobicistat [1], hormonal contraceptives ---> SmPC of [1] of EMA
Co-administration of EVOTAZ and hormonal contraceptives should be avoided. An alternate (non-hormonal) reliable method of contraception is recommended.
Atazanavir/cobicistat [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration of EVOTAZ and hormonal contraceptives should be avoided. An alternate (non-hormonal) reliable method of contraception is recommended.
Atorvastatin [1], oral contraceptives ---> SmPC of [1] of eMC
Co-administration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethindrone and ethinyl oestradiol.
Atorvastatin, oral contraceptives ---> SmPC of [ezetimibe/atorvastatin] of eMC
Coadministration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethisterone and ethinyl estradiol.
Azithromycin, contraceptives
Azithromycin may decrease contraceptive's efficacy of oral contraceptives.
Barbiturates, oral contraceptives ---> SmPC of [ethinylestradiol/desogestrel] of eMC
The enzymatic induction may accelerate the metabolism of steroid hormones and decrease their plasma levels and effect.
Bexarotene [1], oral contraceptives ---> SmPC of [1] of EMA
Bexarotene can potentially induce metabolic enzymes and thereby theoretically reduce the efficacy of oestroprogestive contraceptives.
Bile-acid sequestrants, contraceptives
Bile acid sequestrants may decrease the serum concentration of contraceptives. Administer the sequestrant 4 hours after the contraceptive
Bisacodyl, oral contraceptives
The co-administration may decrease the absorption of the oral contraceptive
Bortezomib [1], contraceptives ---> SmPC of [1] of EMA
Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment.
Bosentan [1], oral contraceptives ---> SmPC of [1] of EMA
Hormone-based contraceptives alone, regardless of the route of administration (i.e., oral, injectable, transdermal or implantable forms), are not considered as reliable methods of contraception
Breast-feeding, contraceptives
Lactation may be influenced by combination hormonal contraceptives as they may reduce the quantity and change the composition of breast milk
Breast-feeding, oral contraceptives
Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the breast milk
Brivaracetam [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance.
Budesonide [1], oral contraceptives ---> SmPC of [1] of EMA
Elevated plasma concentrations and enhanced effects of glucocorticosteroids have been reported in women also receiving oestrogens or oral contraceptives.
Cabotegravir [1], oral contraceptives ---> SmPC of [1] of EMA
Cabotegravir did not significantly change ethinyl estradiol and levonorgestrel plasma concentrations to a clinically relevant extent. No dose adjustment of oral contraceptives is necessary when co- administered with Vocabria.
Cabozantinib [1], oral contraceptives ---> SmPC of [1] of EMA
As unchanged contraceptive effect may not be guaranteed, an additional contraceptive method, such as a barrier method, is recommended.
Caffeine, oral contraceptives
Decreased caffeine elimination
Canagliflozin [1], oral contraceptives ---> SmPC of [1] of EMA
Interaction studies suggest that the pharmacokinetics of canagliflozin are not altered by metformin, hydrochlorothiazide, oral contraceptives (ethinyl estradiol and levonorgestrol), ciclosporin, and/or probenecid.
Carbamazepine [1], oral contraceptives ---> SmPC of [1] of eMC
Carbamazepine may lower the plasma level of oral contraceptive
Carfilzomib [1], oral contraceptives ---> SmPC of [1] of EMA
It is unknown whether carfilzomib is an inducer of CYP1A2, 2C8, 2C9, 2C19 and 2B6 at therapeutic concentrations. Caution should be observed when carfilzomib is combined with products that are substrates of these enzymes, such as oral contraceptives.
Cariprazine [1], hormonal contraceptives ---> SmPC of [1] of EMA
Women using systemically acting hormonal contraceptives should add a second barrier method.
Cefadroxil, oral contraceptives
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Cefotaxime, oral contraceptives
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Cefpodoxime, oral contraceptives
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Ceftriaxone [1], oral contraceptives ---> SmPC of [1] of eMC
Ceftriaxone may adversely affect the efficacy of oral hormonal contraceptives. Consequently, it is advisable to use supplementary (non-hormonal) contraceptive measures during treatment and in the month following treatment.
Cenobamate [1], hormonal contraceptives ---> SmPC of [1] of EMA
Since hormonal contraceptives may also be metabolized by CYP3A4, their efficacy may be reduced by concomitant use with cenobamate.
Cephalosporins, oral contraceptives
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Ceritinib [1], oral contraceptives ---> SmPC of [1] of EMA
The effectiveness of concomitant administration of oral contraceptives may be reduced.
Chenodeoxycholic acid [1], oral contraceptives ---> SmPC of [1] of EMA
The administration of oral contraceptives reduces the pool size of chenodeoxycholic acid. Co-administration with oral contraceptives is not recommended.
Chlordiazepoxide, oral contraceptives
Decreased chlordiazepoxide elimination rate
Chlorpromazine, oral contraceptives
The moderate CYP1A2 inhibition may increase the plasma levels of chlorpromazine (small therapeutic range)
Chlorprothixene, oral contraceptives
The enzymatic inhibition increases the plasma levels of chlorprothixene
Chlortetracycline, oral contraceptives
The effect of hormonal contraceptives may be decreased
Clindamycin [1], oral contraceptives ---> SmPC of [1] of eMC
Clindamycin possibly reduces the contraceptive effect of oestrogen. Though the risk is small, additional contraceptive precautions are recommended during concomitant use and for 7 days after discontinuing clindamycin.
Clofibric acid, oral contraceptives
Combination hormonal contraceptives with clofibric acid may decrease plasma (due to induction of glucuronidation) of clofibric acid
Cobicistat [1], oral contraceptives ---> SmPC of [1] of EMA
Concentrations of contraceptive components may be affected on co-administration with cobicistat. Alternative forms of contraception should be used.
Colesevelam [1], oral contraceptives ---> SmPC of [1] of EMA
Colesevelam can affect the bioavailability of the oral contraceptive pill when administered simultaneously. It is important to ensure that colesevelam is administered at least 4 hours after the oral contraceptive pill
Colestilan [1], oral contraceptives ---> SmPC of [1] of EMA
Reduced bioavailability of other medicinal products been reported. You should the other medicine up to 1 hour prior to or 3 hours following colestilan
Combination oral contraceptives, insulin ---> SmPC of [ethinylestradiol/gestodene] of eMC
Oral contraceptives may decrease glucose tolerance resulting in hyperglycemia and decreased efficacy of oral antidiabetics and insulin
Combination oral contraceptives, oral anticoagulants ---> SmPC of [ethinylestradiol/gestodene] of eMC
Oral contraceptives may decrease the effect of oral anticoagulants probably due to an antagonist effect on some coagulation factors
Contraceptive steroids, letermovir [2] ---> SmPC of [2] of EMA
Letermovir may reduce plasma concentrations of other oral contraceptive steroids thereby affecting their efficacy.
Contraceptive steroids, vismodegib [2] ---> SmPC of [2] of EMA
Enzym induction by vismodegib could lead to decreases in systemic exposure of the contraceptive steroids and thereby reduced contraceptive efficacy.
Contraceptives, CYP3A4 inductors
The CYP3A4 induction may decrease the concentrations of the steroid and even contraceptive failure
Contraceptives, CYP3A4 inhibitors
The CYP3A4 inhibition may increase the concentrations of the steroid.
Contraceptives, dabrafenib [2] ---> SmPC of [2] of EMA
Dabrafenib may decrease the efficacy of hormonal contraceptives and an alternate method of contraception should be used
Contraceptives, decitabine [2] ---> SmPC of [2] of EMA
Women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Dacogen. The time period following treatment with Dacogen where it is safe to become pregnant is unknown.
Contraceptives, defibrotide [2] ---> SmPC of [2] of EMA
Effective contraception is required for patients and partners of patients during exposure to Defitelio and for one week subsequent to discontinuation.
Contraceptives, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 ç—¢ ethinylestradiol and containing norgestimate as the progestagen or should use an alternative reliable method of contraception
Contraceptives, emtricitabine/rilpivirine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
The use of Odefsey should be accompanied by the use of effective contraception.
Contraceptives, glycerol phenylbutyrate [2] ---> SmPC of [2] of EMA
Effective contraceptive measures must be taken by women of child-bearing potential
Contraceptives, josamycin
The effect of hormonal contraceptive can be reduced.
Contraceptives, kebuzone
Possible decrease of anticonceptive effect
Contraceptives, ketoconazole [2] ---> SmPC of [2] of EMA
Women must be provided with comprehensive information on pregnancy prevention. As a minimum requirement, women of childbearing potential must use an effective method of contraception
Contraceptives, lofepramine
The oral contraceptive antagonises the antidepressant effect but side-effects may be increased due to increased plasma concentrations of tricyclic.
Contraceptives, lopinavir/ritonavir [2] ---> SmPC of [2] of EMA
In case of co-administration of lopinavir/ritonavir with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used.
Contraceptives, macrolide antibiotics
The effect of hormonal contraceptive can be reduced.
Contraceptives, midostaurin [2] ---> SmPC of [2] of EMA
It is currently unknown whether midostaurin may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier method of contraception
Contraceptives, neratinib [2] ---> SmPC of [2] of EMA
Women using systemically acting hormonal contraceptives should add a barrier method
Contraceptives, nevirapine [2] ---> SmPC of [2] of EMA
Hormonal methods of birth control other than Depot-medroxyprogesterone acetate (DMPA) should not be used as the sole method of contraception in women taking nevirapine, since nevirapine might lower the plasma concentrations of these medicinal products.
Contraceptives, olaparib [2] ---> SmPC of [2] of EMA
The efficacy of hormonal contraceptives may be reduced if co-administered with olaparib
Contraceptives, olaratumab [2] ---> SmPC of [2] of EMA
Women of childbearing potential should be advised to use effective contraception during treatment and for at least 3 months following the last dose of olaratumab.
Contraceptives, palbociclib [2] ---> SmPC of [2] of EMA
Women of childbearing potential or their male partners must use a highly effective method of contraception while taking IBRANCE
Contraceptives, paracetamol
Oral contraceptive may increase the paracetamol clearance.
Contraceptives, pegvisomant [2] ---> SmPC of [2] of EMA
Female patients should use adequate contraception as fertility may be increased.
Contraceptives, phenobarbital
The enzyme inducing effect of phenobarbital may decrease the contraceptive efficacy
Contraceptives, sodium phenylbutyrate [2] ---> SmPC of [2] of EMA
Effective contraceptive measures must be taken by women of child-bearing potential.
Contraceptives, sofosbuvir/velpatasvir/voxilaprevir [2] ---> SmPC of [2] of EMA
Vosevi is contraindicated with ethinylestradiol-containing medicinal products (see section 4.3). Alternative methods of contraception (e.g. progestin only contraception or non-hormonal methods) should be considered.
Contraceptives, strong CYP3A4 inductors
The strong CYP3A4 induction may decrease the concentrations of the steroid and even contraceptive failure
Contraceptives, strong CYP3A4 inhibitors
The strong CYP3A4 inhibition may increase the concentrations of the steroid.
Contraceptives, tacrolimus [2] ---> SmPC of [2] of EMA
As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.
Contraceptives, talimogene laherparepvec [2] ---> SmPC of [2] of EMA
Women of childbearing potential should be advised to use an effective method of contraception to prevent pregnancy during treatment with Imlygic.
Contraceptives, thalidomide [2] ---> SmPC of [2] of EMA
Combined hormonal contraceptives are not recommended due to the increased risk of venous thrombo-embolic disease
Contraceptives, tricyclic antidepressant
The oral contraceptive antagonises the antidepressant effect but side-effects may be increased due to increased plasma concentrations of tricyclic.
Contraceptives, venetoclax [2] ---> SmPC of [2] of EMA
It is currently unknown whether venetoclax may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier method.
Contraceptives, vitamin C
The effect of hormonal contraceptive can be reduced at high doses of vitamin C (ascorbic acid).
Crizotinib [1], oral contraceptives ---> SmPC of [1] of EMA
The combination may decrease the effectiveness of oral contraceptive
Cyanocobalamin [1], oral contraceptives ---> SmPC of [1] of eMC
Serum levels of cyanocobalamin may be lowered by oral contraceptives.
Cyclosporine, oral contraceptives ---> SmPC of [norethisterone] of eMC
Oral contraceptives may affect the metabolism of certain other active substances. Accordingly, plasma and tissue concentrations of ciclosporin may increase
Cyproterone/ethinylestradiol [1], oral contraceptives ---> SmPC of [1] of eMC
Concomitant use of cyproterone/ethinylestradiol with another hormonal contraceptive is contraindicated
Daclatasvir [1], oral contraceptives ---> SmPC of [1] of EMA
An oral contraceptive containing ethinylestradiol 35 ç—¢ and norgestimate 0.180/0.215/0.250 mg is recommended with daclatasvir. Other oral contraceptives have not been studied.
Darunavir/ritonavir, oral contraceptives ---> SmPC of [darunavir] of EMA
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered with darunavir and low dose ritonavir.
Deferasirox [1], oral contraceptives ---> SmPC of [1] of EMA
Due to a possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolised through CYP3A4
Deflazacort [1], oral contraceptives ---> SmPC of [1] of eMC
In patients taking estrogens, corticosteroid requirements may be reduced.
Demeclocycline, oral contraceptives [2] ---> SmPC of [2] of eMC
Patients taking oral contraceptives should be warned that if diarrhoea or breakthrough bleeding occur there is a possibility of contraceptive failure.
Diazepam, oral contraceptives
The co-administration may increase the plasma levels of diazepam and cause intermenstrual bleeding
Dimethyl fumarate [1], oral contraceptives ---> SmPC of [1] of EMA
In vitro CYP induction studies did not demonstrate an interaction between Tecfidera and oral contraceptives. Even though an interaction is not expected, non-hormonal contraceptive measures should be considered with Tecfidera
Dolutegravir [1], oral contraceptives ---> SmPC of [1] of EMA
Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with dolutegravir.
Dolutegravir/abacavir/lamivudine [1], oral contraceptives ---> SmPC of [1] of EMA
Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. No dose adjustment of oral contraceptives is necessary when co-administered with dolutegravir.
Dolutegravir/lamivudine [1], oral contraceptives ---> SmPC of [1] of EMA
No dose adjustment of oral contraceptives is necessary when co-administered with Dovato.
Dolutegravir/rilpivirine [1], oral contraceptives ---> SmPC of [1] of EMA
No dose adjustment of oral contraceptives is required when co-administered with Juluca.
Dronedarone [1], oral contraceptives ---> SmPC of [1] of EMA
No decreases in ethinylestradiol and levonorgestrel were observed in healthy subjects receiving dronedarone (800 mg twice daily) concomitantly with oral contraceptives.
Dulaglutide [1], oral contraceptives ---> SmPC of [1] of EMA
No dose adjustment of oral contraceptives is necessary when administered with dulaglutide.
Duloxetine [1], oral contraceptives ---> SmPC of [1] of EMA
Results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A. Specific in vivo drug interaction studies have not been performed.
Efavirenz [1], oral contraceptives ---> SmPC of [1] of EMA
A reliable method of barrier contraception must be used in addition to hormonal contraceptives
Elvitegravir [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration of elvitegravir with oral contraceptives containing progestagens other than norgestimate has not been studied and, therefore, should be avoided.
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [1], oral contraceptives ---> SmPC of [1] of EMA
The effect of co-administration of Genvoya with oral contraceptives containing progestagens other than norgestimate is not known and, therefore, should be avoided.
Encorafenib [1], hormonal contraceptives ---> SmPC of [1] of EMA
Concomitant use with agents that are substrates of CYP3A4 (e.g., hormonal contraceptives) may result in increased toxicity or loss of efficacy of these agents. Agents that are CYP3A4 substrates should be co-administered with caution.
Entrectinib [1], hormonal contraceptives ---> SmPC of [1] of EMA
It is currently unknown whether entrectinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives are advised to add a barrier method
Erenumab [1], oral contraceptives ---> SmPC of [1] of EMA
No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in studies with healthy volunteers.
Eslicarbazepine [1], oral contraceptives ---> SmPC of [1] of EMA
Eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives. Additional non-hormonal forms of contraception are recommended when using Zebinix
Ethosuximide, oral contraceptives
Increased clearance of sex hormones and decreased of the contraceptive effect
Exenatide [1], oral contraceptives ---> SmPC of [1] of EMA
Administration of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) one hour before immediate-release exenatide did not alter the AUC, Cmax or Cmin of either ethinyl estradiol or levonorgestrel.
Felbamate, oral contraceptives
The enzymatic induction may accelerate the metabolism of steroid hormones and decrease their plasma levels and effect.
Fesoterodine [1], oral contraceptives ---> SmPC of [1] of EMA
Fesoterodine does not impair the suppression of ovulation by oral hormonal contraception. In the presence of fesoterodine there are no changes in the plasma concentrations of combined oral contraceptives containing ethinylestradiol and levonorgestrel.
Flucloxacillin, oral contraceptives [2] ---> SmPC of [2] of eMC
In common with other antibiotics, flucloxacillin may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of the combined oral contraceptive.
Fluconazole [1], oral contraceptives ---> SmPC of [1] of eMC
Fluconazole 200 mg daily increased the AUCs of ethinyl estradiol and levonorgestrel 40% and 24%, respectively. Multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.
Flunarizine, oral contraceptives ---> SmPC of [ethinylestradiol/gestodene] of eMC
It has been observed that concomitant use of flunarizine and oral contraceptives increases the risk of galactorrhea
Folates, oral contraceptives
Drugs that may adversely affect the absorption or metabolism of folic acid may cause statuses of folate deficiency
Folates, oral contraceptives ---> SmPC of [folic acid] of eMC
Drugs that may adversely affect the absorption or metabolism of folic acid may cause statuses of folate deficiency
Folic acid, oral contraceptives
Drugs that may adversely affect the absorption or metabolism of folic acid may cause statuses of folate deficiency
Fosamprenavir/ritonavir, oral contraceptives ---> SmPC of [fosamprenavir] of EMA
Because there may be an increased risk of hormonal levels may be altered with co-administration of fosamprenavir, ritonavir and oral contraceptives, alternative non-hormonal methods of contraception are recommended for women of childbearing potential
Fosaprepitant [1], oral contraceptives ---> SmPC of [1] of EMA
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Fostemsavir [1], oral contraceptives ---> SmPC of [1] of EMA
Doses of oestrogen-based therapies, including oral contraceptives, should not contain more than 30 ç—¢ of ethinyl oestradiol per day in patients who are receiving fostemsavir.
Frovatriptan [1], oral contraceptives ---> SmPC of [1] of eMC
In female subjects taking oral contraceptives, concentrations of frovatriptan were 30% higher than in females not taking oral contraceptives. No increased incidence in the adverse event profile was reported.
Gabapentin [1], oral contraceptives ---> SmPC of [1] of eMC
Coadministration of gabapentin with oral contraceptives containing norethindrone and/or ethinyl estradiol, does not influence the steady-state pharmacokinetics of either component.
Gilteritinib [1], hormonal contraceptives ---> SmPC of [1] of EMA
It is unknown whether gilteritinib may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier method of contraception.
Glucocorticoids, oral contraceptives
The co-administration may increase the plasma levels of glucocorticoid
Griseofulvin, oral contraceptives
The enzymatic induction may accelerate the metabolism of steroid hormones and decrease their plasma levels and effect.
Guanethidine, oral contraceptives [2] ---> SmPC of [2] of eMC
The anti-hypertensive action of guanethidine may be reduced by oral contraceptives
Guar, oral contraceptives
The co-administration is contraindicated
Hormonal contraceptives, human papillomavirus 9-valent vaccine (recombinant, adsorbed) [2] ---> SmPC of [2] of EMA
Use of hormonal contraceptives did not appear to affect the type specific immune responses to Gardasil 9
Hormonal contraceptives, human papillomavirus vaccine [2] ---> SmPC of [2] of EMA
Use of hormonal contraceptives did not appear to affect the immune response to Gardasil.
Hormonal contraceptives, idelalisib [2] ---> SmPC of [2] of EMA
Women using hormonal contraceptives should add a barrier method as a second form of contraception since it is currently unknown whether idelalisib may reduce the effectiveness of hormonal contraceptives.
Hormonal contraceptives, lamotrigine ---> SmPC of [ethinylestradiol/desogestrel] of eMC
Oral contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may be decreased (e.g., lamotrigine)
Hormonal contraceptives, larotrectinib [2] ---> SmPC of [2] of EMA
It is currently unknown whether larotrectinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should be advised to add a barrier method.
Hormonal contraceptives, lesinurad [2] ---> SmPC of [2] of EMA
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness
Hormonal contraceptives, lorlatinib [2] ---> SmPC of [2] of EMA
Concurrent administration of lorlatinib with CYP3A4/5 substrates with narrow therapeutic indices, should be avoided since the concentration of these medicinal products may be reduced by lorlatinib
Hormonal contraceptives, lumacaftor/ivacaftor [2] ---> SmPC of [2] of EMA
Hormonal contraceptives should not be relied upon as an effective method of contraception when co-administered with lumacaftor/ivacaftor. Lumacaftor/ivacaftor may decrease the exposure of hormonal contraceptives, which may reduce their efficacy.
Hormonal contraceptives, metreleptin [2] ---> SmPC of [2] of EMA
Since it cannot be excluded that metreleptin may reduce exposure to substrates of CYP3A through enzyme induction, the efficacy of hormonal contraceptives may be reduced if co-administered with metreleptin.
Hormonal contraceptives, osilodrostat [2] ---> SmPC of [2] of EMA
If hormonal contraceptives other than the oral combination of ethinylestradiol and levonorgestrel are used, an additional barrier method of contraception is recommended
Hormonal contraceptives, osimertinib [2] ---> SmPC of [2] of EMA
A risk for decreased exposure of hormonal contraceptives cannot be excluded.
Hormonal contraceptives, selexipag [2] ---> SmPC of [2] of EMA
Since selexipag did not affect the exposure to the CYP3A4 substrate R-warfarin or to the CYP2C9 substrate S-warfarin, reduced efficacy of hormonal contraceptives is not expected.
Hormonal contraceptives, sugammadex [2] ---> SmPC of [2] of EMA
For hormonal contraceptives a clinically relevant capturing interaction could not be excluded (no displacement interactions are expected).
Hormonal contraceptives, tivozanib [2] ---> SmPC of [2] of EMA
It is currently unknown whether tivozanib may reduce the effectiveness of hormonal contraceptives and therefore women using hormonal contraceptives should add a barrier method.
Hormonal contraceptives, trifluridine/tipiracil [2] ---> SmPC of [2] of EMA
It is unknown whether Lonsurf may reduce the effectiveness of hormonal contraceptives. Therefore, women using hormonal contraceptive must also use a barrier contraceptive method.
Human insulin [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increasing in patient's insulin requirement
Imipramine [1], oral contraceptives ---> SmPC of [1] of eMC
Drugs which activate the hepatic mono-oxygenase enzyme system may accelerate the metabolism and lower plasma concentrations of imipramine, resulting in decreased efficacy.
Insulin aspart [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the insulin requirements
Insulin degludec [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the insulin requirements
Insulin degludec/insulin aspart [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the insulin requirements
Insulin degludec/liraglutide [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the Xultophy requirements. The contraceptive effect is anticipated to be unaffected when co-administered with liraglutide.
Insulin detemir [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the insulin requirements
Insulin glargin [1], oral contraceptives ---> SmPC of [1] of EMA
Possible increase of the insulin requirements
Insulin glargine/lixisenatide [1], oral contraceptives ---> SmPC of [1] of EMA
The reduction in Cmax is of limited clinical relevance and no dose adjustment for oral contraceptives is required.
Insulin glulisin [1], oral contraceptives ---> SmPC of [1] of EMA
Possible decrease in blood-glucose-lowering activity
Insulin lispro [1], oral contraceptives ---> SmPC of [1] of EMA
Insulin requirements may be increased by medicinal products with hyperglycaemic activity
Ivacaftor [1], oral contraceptives ---> SmPC of [1] of EMA
Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Ivacaftor is not expected to modify the efficacy of oral contraceptives.
Ixazomib [1], oral contraceptives ---> SmPC of [1] of EMA
When NINLARO is administered together with dexamethasone, which is known to be a weak to moderate inducer of CYP3A4 as well as other enzymes and transporters, the risk for reduced efficacy of oral contraceptives needs to be considered.
Lacosamide [1], oral contraceptives ---> SmPC of [1] of EMA
In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered.
Lamivudine/raltegravir [1], oral contraceptives ---> SmPC of [1] of EMA
No dosage adjustment required for lamivudine/raltegravir or hormonal contraceptives (oestrogen-and/or progesterone-based).
Lamotrigine, oral contraceptives
Oral contraceptives may affect the metabolism of other medicinal products. Special attention should be paid to the interaction with lamotrigine.
Lamotrigine, oral contraceptives ---> SmPC of [ethinylestradiol/desogestrel] of eMC
Oral contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may be decreased (e.g. lamotrigine)
Leflunomide [1], oral contraceptives ---> SmPC of [1] of EMA
While the interaction is not expected to adversely impact the efficacy of oral contraceptives, consideration should be given to the type of oral contraceptive treatment.
Lenalidomide [1], oral contraceptives ---> SmPC of [1] of EMA
It may not be excluded that the efficacy of oral contraceptives may be reduced during treatment. Effective measures to avoid pregnancy must be taken
Lenvatinib [1], oral contraceptives ---> SmPC of [1] of EMA
It is currently unknown whether lenvatinib may reduce the effectiveness of hormonal contraceptives, and therefore women using oral hormonal contraceptives should add a barrier method
Levacetylmethadol [1], oral contraceptives ---> SmPC of [1] of EMA
The efficacy of oral contraceptives might be reduced by levacetylmethadol. The use of another contraceptive method (e.g. barrier method) is recommended.
Levetiracetam [1], oral contraceptives ---> SmPC of [1] of EMA
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Light paraffin, oral contraceptives
The co-administration of paraffin oil and oral contraceptives may decrease the absorption of the oral contraceptive
Linaclotide [1], oral contraceptives ---> SmPC of [1] of EMA
The efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception
Linagliptin [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol.
Linagliptin/metformin [1], oral contraceptives ---> SmPC of [1] of EMA
Co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol.
Liraglutide [1], oral contraceptives ---> SmPC of [1] of EMA
The contraceptive effect is anticipated to be unaffected when co-administered with liraglutide.
Lixisenatide [1], oral contraceptives ---> SmPC of [1] of EMA
Following administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol/levonorgestrel) 1 hour before or 11 hours after 10 mcg lixisenatide, the Cmax, AUC, t1/2 and tmax of ethinylestradiol and levonorgestrel were unchanged
Lomitapide [1], oral contraceptives ---> SmPC of [1] of EMA
Patients taking oestrogen-based oral contraceptives should be advised about possible loss of effectiveness due to diarrhoea and/or vomiting. Oestrogen-containing oral contraceptives are weak CYP3A4 inhibitors
Lurasidone [1], oral contraceptives ---> SmPC of [1] of EMA
Lurasidone can be coadministered with oral contraceptives.
Lymecycline, oral contraceptives [2] ---> SmPC of [2] of eMC
Although not reported for lymecycline, a few cases of pregnancy or breakthrough bleeding have been attributed to the concurrent use of tetracycline or oxytetracycline with oral contraceptives.
Macitentan [1], oral contraceptives ---> SmPC of [1] of EMA
Macitentan 10 mg once daily did not affect the pharmacokinetics of an oral contraceptive (norethisterone 1 mg and ethinyl estradiol 35 ç—¢).
Meprobamate, oral contraceptives [2] ---> SmPC of [2] of eMC
Like barbiturates, meprobamate can cause induction of liver enzymes, so that the availability and blood levels of drugs given concurrently that are metabolised in the liver may be affected.
Metformin, oral contraceptives
Decreased hypoglycemic effect
Methotrexate [1], oral contraceptives ---> SmPC of [1] of EMA
Displacement of methotrexate from serum albumin binding and thus increase bioavailability (indirect dose increase).
Methylprednisolone, oral contraceptives
Increased glucocorticoid effect
Metoclopramide, oral contraceptives
The co-administration of metoclopramide and oral contraceptives may decrease the systemic absorption and efficacy of oral contraceptives
Morphine, oral contraceptives ---> SmPC of [ethinylestradiol/norgestimate] of eMC
Combination hormonal contraceptives with morphine may decrease plasma (due to induction of glucuronidation) of morphine
Moxifloxacin [1], oral contraceptives ---> SmPC of [1] of eMC
Clinical studies have shown no interactions following concomitant administration of moxifloxacin with oral contraceptives
Mycophenolate mofetil [1], oral contraceptives ---> SmPC of [1] of EMA
Pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil
Mycophenolate [1], oral contraceptives ---> SmPC of [1] of EMA
Pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil
Naratriptan [1], oral contraceptives ---> SmPC of [1] of eMC
The oral contraceptive decreases the total clearance of naratriptan. But no dosing adjustments are required.
Netupitant/palonosetron [1], oral contraceptives ---> SmPC of [1] of EMA
Clinical effects on the efficacy of hormonal contraception are unlikely. No relevant changes of netupitant and palonosetron pharmacokinetics were observed.
Nomegestrol/estradiol [1], oral contraceptives ---> SmPC of [1] of EMA
Oral contraceptives may affect the metabolism of other medicinal products. Special attention should be paid to the interaction with lamotrigine.
Norfloxacin, oral contraceptives
It is reported that some antibiotics reduce the effect of oral contraceptives
Omeprazole, oral contraceptives ---> SmPC of [ethinylestradiol/norgestimate] of eMC
Combination hormonal contraceptives with omeprazol may increase plasma levels (due to CYP inhibition) of omeprazol
Oral anticoagulants, oral contraceptives ---> SmPC of [cyproterone/ethinylestradiol] of eMC
Oral contraceptives may decrease the effect of oral anticoagulants probably due to an antagonist effect on some coagulation factors
Oral antidiabetics, oral contraceptives ---> SmPC of [cyproterone/ethinylestradiol] of eMC
Oral contraceptives may decrease glucose tolerance resulting in hyperglycemia and decreased efficacy of oral antidiabetics and insulin
Oral contraceptives, orlistat [2] ---> SmPC of [2] of EMA
Orlistat may indirectly reduce the availability of oral contraceptives and lead to unexpected pregnancies in some individual cases. An additional contraceptive method is recommended in case of severe diarrhoea
Oral contraceptives, oxcarbazepine [2] ---> SmPC of [2] of eMC
Concurrent use of oxcarbazepine with hormonal contraceptives may render these contraceptives ineffective. Another reliable contraceptive method should be used.
Oral contraceptives, oxytetracycline [2] ---> SmPC of [2] of eMC
There is a slight risk of adverse effect on oral contraception.
Oral contraceptives, palbociclib [2] ---> SmPC of [2] of EMA
DDI studies of palbociclib with oral contraceptives have not been conducted
Oral contraceptives, panobinostat [2] ---> SmPC of [2] of EMA
Women using hormonal contraceptives should additionally use a barrier method of contraception.
Oral contraceptives, pegaspargase [2] ---> SmPC of [2] of EMA
An indirect interaction cannot be ruled out between pegaspargase and oral contraceptives due to pegaspargase hepatotoxicity that may impair the hepatic clearance of oral contraceptives.
Oral contraceptives, penicillins
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Oral contraceptives, perampanel [2] ---> SmPC of [2] of EMA
At doses of 12 mg/day Fycompa may decrease the effectiveness of progestative-containing hormonal contraceptives; in this circumstance additional non-hormonal forms of contraception are recommended when using Fycompa
Oral contraceptives, perazine
The co-administration of oral contraceptive may inhibit the metabolism of phenothiazines, what may enhance the effects and adverse reactions
Oral contraceptives, pethidine
The co-administration should be avoided due to inhibition of pethidine metabolism
Oral contraceptives, phenazone
Concomitant use of phenazone and oral contraceptives delays the elimination of phenazone. There is the possibility of an accumulation
Oral contraceptives, phenothiazines
The co-administration of oral contraceptive may inhibit the metabolism of phenothiazines, what may enhance the effects and adverse reactions
Oral contraceptives, phenoxymethylpenicillin [2] ---> SmPC of [2] of eMC
Penicillin may reduce the efficacy of combined oral contraceptives.
Oral contraceptives, phenprocoumon
The co-administration may increase the clearance of phenprocoumon
Oral contraceptives, phenytoin
Phenytoin may decrease the efficacy of oral contraceptives
Oral contraceptives, pioglitazone ---> SmPC of [pioglitazone/metformin] of EMA
Interactions with substances metabolised by these enzymes (see cytochrome P450), e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Oral contraceptives, pioglitazone/metformin [2] ---> SmPC of [2] of EMA
Interactions with substances metabolised by these enzymes (see cytochrome P450), e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.
Oral contraceptives, piperacillin
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Oral contraceptives, piperaquine/artenimol [2] ---> SmPC of [2] of EMA
When co-administered to healthy women, Eurartesim exerted only a minimum effect on an estrogen/progestinic combination oral contraceptive treatment
Oral contraceptives, pitolisant [2] ---> SmPC of [2] of EMA
With oral contraceptives, the combination with pitolisant should be avoided and a further reliable contraceptive method used.
Oral contraceptives, pomalidomide [2] ---> SmPC of [2] of EMA
The potential for such drug-drug interactions, including the potential impact of pomalidomide on the pharmacokinetics of combined oral contraceptives, has not been evaluated clinically
Oral contraceptives, prajmalium
The co-administration of prajmalium with hormones (oral contraceptives) increases the frequency of long-lasting cholestasis
Oral contraceptives, prazepam
The oral contraceptive may enhance the effect of prazepam
Oral contraceptives, prednisolone ---> SmPC of [ethinylestradiol/norgestimate] of eMC
Combination hormonal contraceptives with prednisolone may increase plasma levels (due to CYP inhibition) of prednisolone
Oral contraceptives, prednisone [2] ---> SmPC of [2] of eMC
May enhance the efficacy of glucocorticoids.
Oral contraceptives, pregabalin [2] ---> SmPC of [2] of EMA
Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.
Oral contraceptives, primidone
Primidone therapy may lead to altered pharmacokinetics in concomitantly administered drugs, whose metabolism may be increased and lead to lowered plasma levels and/or a shorter half-life.
Oral contraceptives, prucalopride [2] ---> SmPC of [2] of EMA
Prucalopride had no clinically relevant effects on the pharmacokinetics of oral contraceptives.
Oral contraceptives, pyridostigmine
The oral contraceptive may decrease the effects of pyridostigmine
Oral contraceptives, pyridoxine [2] ---> SmPC of [2] of eMC
Oral contraceptives may increase the requirements for pyridoxine
Oral contraceptives, repaglinide [2] ---> SmPC of [2] of EMA
Oral contraceptives may reduce the hypoglycaemic effect of repaglinide
Oral contraceptives, retigabine [2] ---> SmPC of [2] of EMA
No clinically significant effect of retigabine there was on the pharmacokinetics of the estrogen (ethinyl estradiol)/progestogen (norethindrone) nor low dose combination oral contraceptive on the pharmacokinetics of retigabine.
Oral contraceptives, retinol
Concomitant use of oral contraceptives with vitamin A may increase the plasma levels of vitamin
Oral contraceptives, ribociclib [2] ---> SmPC of [2] of EMA
Drug-drug interaction studies between ribociclib and oral contraceptives have not been conducted
Oral contraceptives, rifabutin [2] ---> SmPC of [2] of eMC
Rifabutin has been shown to induce the enzymes of the cytochrome P450 3A subfamily and therefore may affect the pharmacokinetic behaviour of drugs metabolised by the enzymes belonging to this subfamily.
Oral contraceptives, rifampicin [2] ---> SmPC of [2] of eMC
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.
Oral contraceptives, ritonavir [2] ---> SmPC of [2] of EMA
Ritonavir adversely interacts with oral contraceptives. Therefore, an alternative, effective and safe method of contraception should be used during treatment
Oral contraceptives, rosuvastatin [2] ---> SmPC of [2] of eMC
Concomitant use of rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses
Oral contraceptives, rotigotine [2] ---> SmPC of [2] of EMA
Co-administration of rotigotine (3 mg/24 h) did not affect the pharmacodynamics and pharmacokinetics of oral contraceptives (0.03 mg ethinylestradiol, 0.15 mg levonorgestrel).
Oral contraceptives, rucaparib [2] ---> SmPC of [2] of EMA
Interactions between rucaparib and oral contraceptives have not been studied.
Oral contraceptives, rufinamide [2] ---> SmPC of [2] of EMA
Women of child-bearing potential using hormonal contraceptives are advised to use an additional safe and effective contraceptive method
Oral contraceptives, ruxolitinib [2] ---> SmPC of [2] of EMA
A study in healthy subjects indicated that ruxolitinib does not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel.
Oral contraceptives, saquinavir [2] ---> SmPC of [2] of EMA
Because concentration of ethinyl estradiol may be decreased when coadministered with Invirase/ritonavir, alternative or additional contraceptive measures should be used when oestrogen-based oral contraceptives are co-administered
Oral contraceptives, sarilumab [2] ---> SmPC of [2] of EMA
Kevzara may reverse the inhibitory effect of IL-6 and restore CYP3A4 activity, leading to decreased exposure and activity of CYP3A4 substrate.
Oral contraceptives, selegiline ---> SmPC of [ethinylestradiol/norgestimate] of eMC
Combination hormonal contraceptives with selegiline may increase plasma levels (due to CYP inhibition) of selegiline
Oral contraceptives, semaglutide [2] ---> SmPC of [2] of EMA
Semaglutide is not anticipated to decrease the effect of oral contraceptives as semaglutide did not change the overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree
Oral contraceptives, sibutramine
Sibutramine doesn't impair the efficacy of oral contraceptives.
Oral contraceptives, siltuximab [2] ---> SmPC of [2] of EMA
Prescribers should exercise caution when siltuximab is co-administered with medicinal products that are CYP3A4 substrates where a decrease in effectiveness would be undesirable (e.g., oral contraceptives)
Oral contraceptives, siponimod [2] ---> SmPC of [2] of EMA
An effect of siponimod on the efficacy of oral contraceptives is not expected.
Oral contraceptives, sirolimus [2] ---> SmPC of [2] of EMA
The results of a single-dose interaction study cannot exclude the possibility of changes in the pharmacokinetics that might affect the efficacy of the oral contraceptive during long-term treatment with sirolimus.
Oral contraceptives, sitagliptin [2] ---> SmPC of [2] of EMA
In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives
Oral contraceptives, sitaxentan [2] ---> SmPC of [2] of EMA
Sitaxentan sodium did not affect the anti-ovulatory activity of the oral contraceptive as assessed by the plasma concentrations of follicle stimulating hormone (FSH), luteinising hormone (LH), and progesterone
Oral contraceptives, sodium valproate [2] ---> SmPC of [2] of eMC
Valproate usually has no enzyme-inducing effect; as a consequence, valproate does not reduce efficacy of oestroprogestative agents in women receiving hormonal contraception, including the oral contraceptive pill.
Oral contraceptives, sofosbuvir/velpatasvir [2] ---> SmPC of [2] of EMA
No dose adjustment of oral contraceptives is required.
Oral contraceptives, solifenacin [2] ---> SmPC of [2] of eMC
Intake of solifenacin showed no pharmacokinetic interaction of solifenacin on combined oral contraceptives (ethinylestradiol/levonorgestrel).
Oral contraceptives, sotagliflozin [2] ---> SmPC of [2] of EMA
Interaction studies in healthy volunteers showed that metformin, metoprolol, midazolam, rosuvastatin and oral contraceptives had no clinically relevant effect on the pharmacokinetics of sotagliflozin.
Oral contraceptives, spiramycin
Antibiotic may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
Oral contraceptives, St. John's wort [2] ---> SmPC of [2] of eMC
Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort.
Oral contraceptives, succinylcholine ---> SmPC of [suxamethonium] of eMC
The decrease in the normal plasma cholinesterase activity may prolong the neuromuscular blocking effects of suxamethonium
Oral contraceptives, suxamethonium [2] ---> SmPC of [2] of eMC
The decrease in the normal plasma cholinesterase activity may prolong the neuromuscular blocking effects of suxamethonium
Oral contraceptives, talazoparib [2] ---> SmPC of [2] of EMA
Drug-drug interaction studies between talazoparib and oral contraceptives have not been conducted.
Oral contraceptives, tamoxifen [2] ---> SmPC of [2] of eMC
Hormone preparations, particularly oestrogens (e.g. oral contraceptives) should not be combined with tamoxifen because a mutual decrease in effect is possible.
Oral contraceptives, telaprevir [2] ---> SmPC of [2] of EMA
Additional methods of non-hormonal contraception should be used when hormonal contraceptives are co-administered with telaprevir.
Oral contraceptives, telithromycin [2] ---> SmPC of [2] of EMA
There is no pharmacodynamic or clinically relevant pharmacokinetic interaction with low-dose triphasic oral contraceptives in healthy subjects.
Oral contraceptives, temazepam
Combination hormonal contraceptives with temazepam may decrease plasma (due to induction of glucuronidation) of temazepam
Oral contraceptives, terbinafine [2] ---> SmPC of [2] of eMC
Some cases of menstrual disturbance (breakthrough bleeding and irregular cycle) have been reported in patients taking terbinafine concomitantly with oral contraceptives
Oral contraceptives, teriflunomide [2] ---> SmPC of [2] of EMA
While the interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, consideration should be given to the type or dose of oral contraceptives used in combination with teriflunomide.
Oral contraceptives, tetracyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives
Oral contraceptives, tetracyclines ---> SmPC of [tigecycline] of EMA
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Oral contraceptives, tezacaftor/ivacaftor [2] ---> SmPC of [2] of EMA
Symkevi in combination with ivacaftor has been studied with an estrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the hormonal contraceptive.
Oral contraceptives, theophylline [2] ---> SmPC of [2] of eMC
The oral contraceptives reduce clearance of theophylline and a reduced dosage may therefore be necessary to avoid side-effects
Oral contraceptives, thiopental
The enzymatic induction by thiopental may decrease the exposition of oral contraceptives
Oral contraceptives, tiagabine [2] ---> SmPC of [2] of eMC
Tiagabine does not have any clinically significant effect on the plasma concentrations of hormones from oral contraceptive pills.
Oral contraceptives, ticagrelor [2] ---> SmPC of [2] of EMA
No clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are co-administered with ticagrelor.
Oral contraceptives, tigecycline [2] ---> SmPC of [2] of EMA
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Oral contraceptives, tipranavir/ritonavir ---> SmPC of [tipranavir] of EMA
Alternative or additional contraceptive measures are to be used when oestrogen based oral contraceptives are co-administered with tipranavir co-administered with low dose ritonavir
Oral contraceptives, tizanidine [2] ---> SmPC of [2] of eMC
Pharmacokinetic data following single and multiple doses of tizanidine suggested that clearance of tizanidine was reduced by approximately 50% in women who were concurrently taking oral contraceptives.
Oral contraceptives, tofacitinib [2] ---> SmPC of [2] of EMA
Coadministration of XELJANZ did not have an effect on the PK of oral contraceptives, levonorgestrel and ethinyl estradiol, in healthy female volunteers.
Oral contraceptives, tolbutamide
Decreased hypoglycaemic effect may occur
Oral contraceptives, tolterodine [2] ---> SmPC of [2] of eMC
Drug interaction studies have shown no interactions with combined oral contraceptives (ethinyl estradiol/levonorgestrel)
Oral contraceptives, topiramate [2] ---> SmPC of [2] of eMC
The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with topiramate.
Oral contraceptives, trazodone [2] ---> SmPC of [2] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives
Oral contraceptives, triamcinolone
Oestrogens, including oral contraceptives may increase corticosteroid half-life and concentration and decrease clearance
Oral contraceptives, triamcinolone acetonide [2] ---> SmPC of [2] of eMC
Oestrogens, including oral contraceptives may increase corticosteroid half-life and concentration and decrease clearance
Oral contraceptives, triazolam
Oral contraceptives may increase plasma levels of triazolam due to inhibition of CYP3A4. It is recommended caution with the concomitant use
Oral contraceptives, tricyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives
Oral contraceptives, trimethoprim
The co-administration may decrease the safety of oral contraceptive
Oral contraceptives, ulipristal [2] ---> SmPC of [2] of EMA
Ulipristal acetate may interfere with the action of hormonal contraceptive products. Medicinal products containing progestagen should not be taken within 12 days after cessation of ulipristal acetate treatment.
Oral contraceptives, ursodeoxycholic acid
Ursodeoxycholic acid adversely interacts with oral contraceptives. Therefore, an alternative, effective and safe method of contraception should be used during treatment
Oral contraceptives, vemurafenib [2] ---> SmPC of [2] of EMA
The efficacy of contraceptive pills metabolised by CYP3A4 used concomitantly with vemurafenib might be decreased.
Oral contraceptives, vitamin A
Concomitant use of oral contraceptives with vitamin A may increase the plasma levels of vitamin
Oral contraceptives, voriconazole [2] ---> SmPC of [2] of EMA
Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended.
Oral contraceptives, warfarin [2] ---> SmPC of [2] of eMC
Oral contraceptives antagonise the effect of warfarin
Oral contraceptives, zafirlukast [2] ---> SmPC of [2] of eMC
Zafirlukast may be administered with oral contraceptives without adverse interaction.
Oral contraceptives, ziprasidone
Oral contraceptives - The use of ziprasidone caused no significant changes of estrogen pharmacokinetics (ethinylestradiol, CYP3A4 substrate) or progesterone derivates
Oral contraceptives, zonisamide [2] ---> SmPC of [2] of EMA
In clinical studies in healthy subjects, steady-state dosing with Zonegran did not affect serum concentrations of ethinylestradiol or norethisterone in a combined oral contraceptive.